Key result
Intracoronary radiotherapy for in-stent restenosis requires thorough and unbiased assessment to establish its safety and efficacy before widespread dissemination.
Answers are grounded in this paper and cite their sources.
Highlights the need for thorough and unbiased assessment of intracoronary radiotherapy for in-stent restenosis prior to widespread clinical adoption.
On November 3, 2000, the Food and Drug Administration (FDA) granted approval for two devices that deliver intracoronary radiotherapy for in-stent restenosis. Given this approval, it is possible that there will be widespread dissemination of this technique before its safety and efficacy have been established. Before interventional cardiologists wholeheartedly embrace this new technology, it should receive a thorough and unbiased assessment by impartial parties.1 More than 500,000 percutaneous coronary revascularization procedures are performed each year in North America.2 Restenosis occurs in 30 to 40 percent of patients within six months after balloon angioplasty and in 20 to 30 percent of . . .
No takes yet. Share an insight, caveat, or question.
Sheppard et al. (2001) conducted an editorial in in-stent restenosis. Intracoronary radiotherapy was evaluated. Intracoronary radiotherapy for in-stent restenosis requires thorough and unbiased assessment to establish its safety and efficacy before widespread dissemination.
Synapse has enriched 10 related papers. Consider them for comparative context: